• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Figure 36 depicts a chart of an odds ratio of hepatotoxicity during thiopurine treatment of chronicautoimmune disease, homozygotes versus noncarriers. The results are an odds ratio of 3.85 and a 95 percent confidence interval of (0.90, 16.5) favoring noncarriers.

Figure 36Odds ratio of hepatotoxicity during thiopurine treatment of chronic autoimmune disease, homozygotes versus noncarriers

From: 3, Results

Cover of Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs
Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-Based Drugs.
Evidence Reports/Technology Assessments, No. 196.
Booth RA, Ansari MT, Tricco AC, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.